West Pharmaceutical Services (WST) Accumulated Depreciation & Amortization (2009 - 2026)

West Pharmaceutical Services' Accumulated Depreciation & Amortization history runs 18 years deep, the most recent figure standing at $45.2 million for Q1 2026.

• In Q1 2026, Accumulated Depreciation & Amortization rose 13.0% year-over-year to $45.2 million; the TTM figure through Mar 2026 stood at $45.2 million (up 13.0% YoY), while the FY2025 annual figure was $171.4 million, up 10.3% from the prior year.
• Accumulated Depreciation & Amortization came in at $45.2 million for Q1 2026 at West Pharmaceutical Services, down from $171.4 million in the prior quarter.
• In the past five years, Accumulated Depreciation & Amortization ranged from a high of $1.3 billion in Q3 2023 to a low of $35.6 million in Q1 2024.
• A 5-year average of $483.2 million and a median of $137.3 million in 2023 frame the typical range for Accumulated Depreciation & Amortization.
• Across the five-year window, Accumulated Depreciation & Amortization gained 13.85% in 2023 and sank 97.18% in 2024, its largest moves.
• West Pharmaceutical Services' Accumulated Depreciation & Amortization stood at $120.6 million in 2022, then advanced by 13.85% to $137.3 million in 2023, then gained by 13.18% to $155.4 million in 2024, then increased by 10.3% to $171.4 million in 2025, then plunged by 73.63% to $45.2 million in 2026.
• According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods registered $45.2 million, $171.4 million, and $43.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison